The National Institute for Health and Care Excellence (NICE) has updated its guidance on the use of cladribine (Mavenclad, Merck) for patients with rapidly evolving severe relapsing-remitting multiple ...

Ocrevus was noninferior to fingolimod in reducing the annualized relapse rate in pediatric patients with relapsing-remitting multiple sclerosis. The Food and Drug Administration (FDA) has approved ...

Relapsing-remitting multiple sclerosis (MS) is commonly treated with parenteral drugs that can lead to adverse events and poor adherence. Three phase 3 randomized trials evaluated the efficacy and ...

Over one-third of MS patients do not fully recover post-relapse, with severity as the strongest predictor of incomplete recovery. Relapse-associated worsening (RAW) is crucial in understanding ...

Fingolimod represents a first-in-class oral sphingosine-1-phosphate receptor modulator approved for adults with relapsing-remitting multiple sclerosis (RRMS). By sequestering lymphocytes in lymphoid ...

- MUSETTE trial was designed to determine whether a higher dose of the currently approved Ocrevus IV 600 mg would provide additional benefit to people living with relapsing multiple sclerosis - - The ...

I was terrified – especially because I’d grown up watching my mum suffer with the same condition.

Women with relapsing-remitting multiple sclerosis (MS), particularly after menopause, experienced a higher risk of relapse-independent worsening, whereas men showed a greater worsening of disability ...

"Medical Journeys" is a set of clinical resources reviewed by doctors, meant for physicians and other healthcare professionals as well as the patients they serve. Each episode of this journey through ...

Late-onset MS patients are more likely to accumulate disability through mechanisms not directly linked to relapses, per a ...

Although certain diets are sometimes touted as solutions for multiple sclerosis, they often lack evidence to support their ...